401 Bay Street
Suite 2704 PO Box 4
Toronto, ON M5H 2Y4
Canada
905-841-2300
https://www.helixbiopharma.com
Sektor(en):
Branche:
Vollzeitmitarbeiter: 9
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Jacek Antas | Chairman & CEO | 68,23k | N/A | N/A |
Mr. Praveen Kumar Varshney F.C.A., FCA, FCPA, LLB | CFO & Corporate Secretary | N/A | N/A | 1966 |
Dr. Gabrielle M. Siegers M.A., Ph.D. | Head of R&D | N/A | N/A | N/A |
Dr. Srikanth Sola | Chief Strategy Officer | N/A | N/A | N/A |
Dr. Christof Boehler | Chief Business Development Officer | N/A | N/A | N/A |
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Helix BioPharma Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.